Zacks Investment Research downgraded shares of PUMA BIOTECHNLG (PBYI) from NEUTRAL to UNDERPERFORM on October 14, 2014, with a target price of $213.80.
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PUMA BIOTECHNLG (PBYI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment